Related Experiment Video

Updated: Feb 15, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

[Cryoglobulinemia and hepatitis C virus infection]

G Garini1, W Catellani, P Manganelli

  • 1Dipartimento di Clinica Medica, Nefrologia e Scienze della Prevenzione, Università, Parma. garini@ipruniv.cce.unipr.it

Recenti Progressi in Medicina
|March 23, 2001
PubMed

Insights

Hepatitis C virus (HCV) infection is common in mixed cryoglobulinemia (MC), leading to distinct MC subtypes. While alpha-interferon shows some benefit, sustained remission for HCV-related MC remains a challenge.

Area of Science:

  • Immunology
  • Virology
  • Hematology

Context:

  • Hepatitis C virus (HCV) infection is highly prevalent in patients with mixed cryoglobulinemia (MC).
  • This association has led to the classification of MC into HCV-negative (MC HCV-) and HCV-positive (MC HCV+) groups.
  • MC HCV- is typically polyclonal and linked to immune activation, while MC HCV+ may represent an indolent B-cell proliferation driven by HCV.

Purpose:

  • To explore the pathogenetic and therapeutic significance of the association between HCV infection and MC.
  • To review the efficacy of current treatments, particularly alpha-interferon (alpha-IFN), for MC HCV+.
  • To discuss strategies for improving sustained response rates and future therapeutic directions.

Summary:

  • HCV infection significantly impacts the clinical and biological presentation of MC, necessitating a distinction between MC HCV- and MC HCV+.
  • Alpha-interferon (alpha-IFN) therapy benefits approximately half of MC HCV+ patients, but long-term remission rates are low (<25%) due to frequent recurrence of viremia and cryoglobulinemia post-treatment.
  • Prolonged alpha-IFN monotherapy or combination therapy with ribavirin are suggested to improve sustained response, with new antiviral agents offering future promise.

Impact:

  • The findings aid in understanding the distinct mechanisms underlying different MC subtypes based on HCV status.
  • Highlights the limitations of current therapies for HCV-related MC and underscores the need for improved treatment strategies.
  • Provides a basis for considering novel antiviral therapies to achieve more durable remissions in patients with HCV-associated cryoglobulinemia.

More Related Videos

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.2K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
256
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
282
What are Viruses?00:50

What are Viruses?

Overview
128.5K
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.4K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
626
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
326